NRX Pharmaceuticals, Inc.

Big Rock Partners Acquisition Corp. (Nasdaq: BRPA), sponsored by Big Rock Partners, conducted its initial public offering in 2020 with a focus on the healthcare and life sciences sector. The blank-check company pursued a business combination with NRX Pharmaceuticals, Inc., a clinical-stage biopharmaceutical firm developing treatments for central nervous system disorders and critical care respiratory conditions. An 8-K was filed with the SEC on July 21, 2022, under NRX Pharmaceuticals as the successor registrant, reflecting post-merger reporting obligations following the completed de-SPAC transaction. The combined company operates in the biopharma space under ongoing SEC reporting requirements. Sign up for full data, filing history, and deal analytics on BRPA and hundreds of other SPAC transactions at SpacDesk.